CSF3 and pancreatic adenocarcinoma: In murine models of pancreatic adenocarcinoma expressing RAS oncogene, the G-CSF-mediated resistance to antivascular endothelial growth factor (VEGF) therapies occurs through activation of RAS/MEK/ERK pathways and an Ets-induced overexpression of G-CSF 22.